{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:38:27Z","timestamp":1793281107026,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-026-00474-8","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:57:13Z","timestamp":1784980633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-yield reactor production of terbium-161 using thin-layer gadolinium-160 targets, simplified chloride based separation and radiolabeling of DOTA based ligands"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-7065","authenticated-orcid":false,"given":"Shakera","family":"Khatoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qaiser","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleem","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"474_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-020-00301-2","author":"ME Alcocer-\u00c1vila","year":"2020","unstructured":"Alcocer-\u00c1vila ME, Ferreira A, Quinto MA, Morgat C, Hindi\u00e9 E, Champion C. Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases. EJNMMI Phys. 2020. https:\/\/doi.org\/10.1186\/s40658-020-00301-2.","journal-title":"EJNMMI Phys"},{"issue":"9","key":"474_CR3","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.2967\/jnumed.122.265039","volume":"64","author":"J Bolcaen","year":"2023","unstructured":"Bolcaen J, et al. Marshalling the potential of auger electron radiopharmaceutical therapy. J Nucl Med. 2023;64(9):1344\u201351. https:\/\/doi.org\/10.2967\/jnumed.122.265039.","journal-title":"J Nucl Med"},{"key":"474_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040536","author":"F Borgna","year":"2021","unstructured":"Borgna F, et al. Simultaneous visualization of 161Tb-and 177Lu-labeled somatostatin analogues using dual-isotope SPECT imaging. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13040536.","journal-title":"Pharmaceutics"},{"issue":"4","key":"474_CR5","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","volume":"49","author":"F Borgna","year":"2022","unstructured":"Borgna F, et al. Combination of terbium-161 with somatostatin receptor antagonists\u2014a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49(4):1113\u201326. https:\/\/doi.org\/10.1007\/s00259-021-05564-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"474_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2967\/jnumed.124.267650","volume":"65","author":"JP Buteau","year":"2024","unstructured":"Buteau JP, et al. Clinical trial protocol for VIOLET: a single-center, phase I\/II trial evaluation of radioligand treatment in patients with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. J Nucl Med. 2024;65(8):1231\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.267650.","journal-title":"J Nucl Med"},{"key":"474_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-024-00696-2","author":"L De Nardo","year":"2024","unstructured":"De Nardo L, et al. Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases. EJNMMI Phys. 2024. https:\/\/doi.org\/10.1186\/s40658-024-00696-2.","journal-title":"EJNMMI Phys"},{"key":"474_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2021.109770","author":"L Desorgher","year":"2021","unstructured":"Desorgher L, Bochud F, Grundler P, Van Der Meulen NP, Bailat C. Determination of the gamma and X-ray emission intensities of terbium-161. Appl Radiat Isot. 2021. https:\/\/doi.org\/10.1016\/j.apradiso.2021.109770.","journal-title":"Appl Radiat Isot"},{"key":"474_CR9","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00259-024-06641-w","volume":"51","author":"J Fricke","year":"2024","unstructured":"Fricke J, et al. First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. Eur J Nucl Med Mol Imaging. 2024;51:2517\u20139. https:\/\/doi.org\/10.1007\/s00259-024-06641-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"474_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2026.112700","volume":"235","author":"EB Furkina","year":"2026","unstructured":"Furkina EB, et al. Separation of 161Tb from thermal neutron irradiated 160Gd targets by extraction chromatography. Appl Radiat Isot. 2026;235:112700. https:\/\/doi.org\/10.1016\/j.apradiso.2026.112700.","journal-title":"Appl Radiat Isot"},{"key":"474_CR22","doi-asserted-by":"publisher","unstructured":"Gizawy MA, El-Din AMS, Borai EH, Mohamed NMA. Production and radiochemical separation of Tb-161 as a feasible beta therapeutic radioisotope from reactor irradiated Gd target. J Chromatogr A. 2024;1737:465439. https:\/\/doi.org\/10.1016\/j.chroma.2024.465439","DOI":"10.1016\/j.chroma.2024.465439"},{"issue":"12","key":"474_CR11","first-page":"1","volume":"4","author":"N Gracheva","year":"2019","unstructured":"Gracheva N, et al. Production and characterization of no- carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy. EJNMMI Radiopharm Chem. 2019;4(12):1\u201316.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"474_CR12","doi-asserted-by":"publisher","unstructured":"International Atomic Energy Agency (IAEA). Therapeutic applications of radionuclides. IAEA-TECDOC-1228. Vienna: IAEA. https:\/\/doi.org\/10.1142\/9789814366243_0019.","DOI":"10.1142\/9789814366243_0019"},{"issue":"10","key":"474_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/met10101390","volume":"10","author":"F Monroy-guzman","year":"2020","unstructured":"Monroy-guzman F, et al. Extraction chromatography materials prepared with HDEHP on different inorganic supports for the separation of gadolinium and terbium. Metals. 2020;10(10):1390.","journal-title":"Metals"},{"key":"474_CR14","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180074","author":"C M\u00fcller","year":"2018","unstructured":"M\u00fcller C, Domnanich KA, Umbricht CA, Van Der Meulen NP. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. Br J Radiol. 2018. https:\/\/doi.org\/10.1259\/bjr.20180074.","journal-title":"Br J Radiol"},{"key":"474_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-025-00390-3","author":"CM Ntihabose","year":"2025","unstructured":"Ntihabose CM, et al. Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals. EJNMMI Radiopharm Chem. 2025. https:\/\/doi.org\/10.1186\/s41181-025-00390-3.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"474_CR1","unstructured":"Nuclear National Data Center (Upton N.Y.) NuDat 2.6. Accessed: Apr. 10, 2026. [Online]. Available: https:\/\/www.nndc.bnl.gov\/nudat3\/"},{"key":"474_CR16","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1007\/s10967-025-10346-1","volume":"334","author":"SK Rizvi","year":"2025","unstructured":"Rizvi SK, Javed A, Khan Q. Synthesis & quality control of [225Ac][Ac-DOTATATE]: feasibility of the targeted alpha therapy (TAT) in conventional clinical pharmacy equipped for Tc-99m in Pakistan. J Radioanal Nucl Chem. 2025;334:6349\u201358. https:\/\/doi.org\/10.1007\/s10967-025-10346-1.","journal-title":"J Radioanal Nucl Chem"},{"issue":"5","key":"474_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.7150\/thno.92273","volume":"14","author":"A Schaefer-Schuler","year":"2024","unstructured":"Schaefer-Schuler A, et al. [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617. Theranostics. 2024;14(5):1829\u201340. https:\/\/doi.org\/10.7150\/thno.92273.","journal-title":"Theranostics"},{"key":"474_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ph19040619","author":"M Sk\u00e1lov\u00e1","year":"2026","unstructured":"Sk\u00e1lov\u00e1 M, Jansk\u00e1 T, Vlk M, \u0160olt\u00e9s J, Vin\u0161 M, Hassfjell S. Practical aspects of 161Tb production. Pharmaceuticals (Basel). 2026. https:\/\/doi.org\/10.3390\/ph19040619.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"474_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25040966","volume":"25","author":"Z Talip","year":"2020","unstructured":"Talip Z, Favaretto C, Geistlich S, Van Der Meulen NP. A step-by-step guide for the novel radiometal production for medical applications: case studies with 68Ga, 44Sc, 177Lu and 161Tb. Molecules. 2020;25(4):966.","journal-title":"Molecules"},{"key":"474_CR20","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","volume":"64","author":"VJ Tschan","year":"2023","unstructured":"Tschan VJ, et al. Albumin-binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy. J Nucl Med. 2023;64:1625\u201331. https:\/\/doi.org\/10.2967\/jnumed.123.265524.","journal-title":"J Nucl Med"},{"key":"474_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2025.112144","author":"M \u017b\u00f3\u0142towska","year":"2025","unstructured":"\u017b\u00f3\u0142towska M, et al. Two-step extraction chromatography separation of 161Tb from 160Gd-enriched irradiated target material and verification of the [161Tb]TbCl3 suitability for radiolabelling. Appl Radiat Isot. 2025. https:\/\/doi.org\/10.1016\/j.apradiso.2025.112144.","journal-title":"Appl Radiat Isot"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00474-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:57:52Z","timestamp":1793278672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00474-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00474-8","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable. This study did not involve human participants, human data, or animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including individual details, images, or videos).","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. All authors explicitly declare that there are no potential conflicts of interest with respect to the experimental research findings, authorship, or publication of this article.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"73"}}